Cyclosporine versus tacrolimus (FK 506) for prevention of cardiac allograft vasculopathy
- 1 January 2000
- journal article
- clinical trial
- Published by Elsevier BV in The American Journal of Cardiology
- Vol. 85 (2), 266-269
- https://doi.org/10.1016/s0002-9149(99)00631-1
Abstract
This study prospectively compared the impact of cyclosporine A and tacrolimus on the development of cardiac allograft vasculopathy. By using serial intravascular ultrasound examinations, a trend toward a more pronounced progression was noted in the tacrolimus group in the first year after heart transplantation.Keywords
This publication has 10 references indexed in Scilit:
- Atherosclerotic coronary lesions with inadequate compensatory enlargement have smaller plaque and vessel volumes: observations with three dimensional intravascular ultrasound in vivoHeart, 1998
- Simvastatin Reduces Graft Vessel Disease and Mortality After Heart TransplantationCirculation, 1997
- A prospective trial of tacrolimus (FK 506) in clinical heart transplantation: Intermediate-term resultsThe Journal of Thoracic and Cardiovascular Surgery, 1996
- Early Endothelial Dysfunction Predicts the Development of Transplant Coronary Artery Disease at 1 Year PosttransplantCirculation, 1996
- Effect of Pravastatin on Outcomes after Cardiac TransplantationNew England Journal of Medicine, 1995
- Simulation Study of Confounder-Selection StrategiesAmerican Journal of Epidemiology, 1993
- Intracoronary ultrasound in cardiac transplant recipients. In vivo evidence of "angiographically silent" intimal thickening.Circulation, 1992
- Effects of cyclosporin, FK506, and rapamycin on graft-vessel diseaseThe Lancet, 1991
- Transplant coronary artery disease: Histopathologic correlations with angiographic morphologyJournal of the American College of Cardiology, 1991
- STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENTThe Lancet, 1986